Evidence map›Paper›PMID 34646847›Full record

ReviewFrontiers in medicine2021

Mitochondrial Regulation of Diabetic Kidney Disease.

Daniel L Galvan, Koki Mise, Farhad R Danesh

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. TFAM and Mitochondrial Protection in Diabetic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Daniel L GalvanSection of Nephrology, The University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Koki MiseSection of Nephrology, The University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Farhad R DaneshSection of Nephrology, The University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USOkayama University · JP

Funding

MicroRNA In Diabetic NephropathyR01DK091310 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANESH, FARHAD R · 2011 to 2024
$5.3M
Role of Rho Kinases in Diabetic NephropathyR01DK078900 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANESH, FARHAD R · 2009 to 2024
$5.2M
NIDDK NIH HHS R01 DK078900NIDDK NIH HHS R01 DK091310
6 · The paper itself

Abstract

The role and nature of mitochondrial dysfunction in diabetic kidney disease (DKD) has been extensively studied. Yet, the molecular drivers of mitochondrial remodeling in DKD are poorly understood. Diabetic kidney cells exhibit a cascade of mitochondrial dysfunction ranging from changes in mitochondrial morphology to significant alterations in mitochondrial biogenesis, biosynthetic, bioenergetics and production of reactive oxygen species (ROS). How these changes individually or in aggregate contribute to progression of DKD remain to be fully elucidated. Nevertheless, because of the remarkable progress in our basic understanding of the role of mitochondrial biology and its dysfunction in DKD, there is great excitement on future targeted therapies based on improving mitochondrial function in DKD. This review will highlight the latest advances in understanding the nature of mitochondria dysfunction and its role in progression of DKD, and the development of mitochondrial targets that could be potentially used to prevent its progression.

Indexed as

bioenergeticsdiabetic kidney diseasemitochondriamitochondrial dynamicsmitochondrial respiratory complexesoxidative phosphorylation

Identifiers

PMID34646847
PMCPMC8502854
OpenAlexW3204527984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.